louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01626313: UCLA FOCUS Family Resiliency Training Research Study
Official title: UCLA FOCUS (Families OverComing Under Stress) Family Resiliency Training Research Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Veteran Families
Family Communications
Civilian Life Reintegration
Keywords: Veteran families
OEF
OIF
OND
Resiliency
Psycho educational training
Stress
Military
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
Collaborators: name: VA Greater Los Angeles Healthcare System
First posted: 2012-06-22
Enrollment: 0
Sex: ALL
Minimum age (years): 5
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study will examine the effectiveness of an eight session, manualized individual family resiliency training (IFRT) for families with one OEF/OIF/OND veteran in promoting better family communication relating to return to post military life.


Eligibility criteria: Inclusion Criteria:

* OEF/OIF/OND Veteran adult family member
* cohabiting with significant other for 6 months or more
* at least one child age 5 to 17 years

Exclusion Criteria:

* active case with Child Protective Services
* conditions or substance use that limits ability to fully participate in the research program

Primary outcomes:
measure: Improvement on standardized behavioral health assessment scales
timeFrame: 4-6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA Semel Institute
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Patricia E Lester, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07023913: Effect of Kinetic Control Exercise on Shoulder Dysfunction Post Mastectomy
Official title: Effect of Kinetic Control Exercise on Shoulder Dysfunction Post Mastectomy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Kinetic Control
Dysfunction
Shoulder
Mastectomy
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-06-17
Enrollment: 60
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of kinetic control exercises on shoulder dysfunction in post-mastectomy.

Detailed description: This study holds significant importance for clinical practice, patient care, and research.

* Clinical Practice: It provides a potential framework for physical therapists to design targeted and effective interventions for shoulder dysfunction in post-mastectomy patients.
* Patient Care: Improved rehabilitation outcomes can enhance patients' physical functionality, independence, and overall quality of life, addressing a critical gap in post-operative recovery.
* Research Advancement: By contributing to the limited body of literature on kinetic control in this context, the study can stimulate further research and innovation in rehabilitative care for breast cancer survivors.

Eligibility criteria: Inclusion Criteria:

The subject selection will be according to the following criteria:

* Age from 40 to 50 years.
* All patients have no diabetes or blood problems.
* All patients enrolled to the study will have their informed consent.

Exclusion Criteria:

The potential participants will be excluded if they meet one of the following criteria:

* Age less than 40 or more 50 years.
* Diabetes mellitus.
* Subjects with lymphedema
* Subjects suffering from active malignant tumors.
* Subjects treated with skin graft.
* Subjects with Mental illness.
* Subjects with skin diseases
* Subjects with any previous cause for shoulder dysfunction

Primary outcomes:
measure: assessment of change of range of motion
timeFrame: at baseline and after 8 weeks
Secondary outcomes:
measure: assessment of ability to maintain controlled shoulder movements while stabilizing the scapular and shoulder
timeFrame: at baseline and after 8 weeks
measure: assessment of ability to maintain controlled shoulder movements while stabilizing the scapular and shoulder
timeFrame: at baseline and after 8 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: learning hospitals Al Kaser Al Ayni hospital
Study officials:
References:
Clinical trial NCT03914313: Robotics Plus VR in Improving Cognition
Official title: Effects of Robotic Neurorehabilitation Plus Virtual Reality on Attention Process and Executive Functions in Patients With Chronic Stroke: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cognition Disorders
Keywords: Lokomat
Robotic rehab
Executive function
VR
Lead sponsor: IRCCS Centro Neurolesi Bonino Pulejo
Sponsor class: OTHER
First posted: 2019-04-16
Enrollment: 90
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Stroke can be classified as ischemic, i.e. due to the lack of blood flow, and haemorrhagic, caused by bleeding. Stroke results in focal signs and symptoms, with a devastating impact on a patient and his family. Although robotic rehabilitation is very useful in improving motor function, there is no a clear evidence on its role in improving cognitive abilities, which are often compromised in stroke patients.

To this end, the investigators designed a randomized controlled experimental study on stroke patients, with the aim of evaluating the effects of robotic neurorehabilitation using Lokomat with and without virtual reality on cognitive functioning in stroke patients, compared to traditional therapy.


Eligibility criteria: Inclusion Criteria:

Neurological diagnosis of stroke in the post-acute phase (3 months from the acute event); age between 40 and 80; and Caucasian ethnicity; a FIM motor score equal to or greater than 30 and moderate to mild cognitive impairment (MoCA\> 18); Fugl-Meyer scale score of\> 18;

Exclusion Criteria:

Patients with a history of concomitant neurodegenerative diseases or brain surgery; severe cognitive or language impairment; systemic, bone or joint disorders; presence of disabling sensory alterations; concomitant medical and psychiatric illness that could interfere with VR training.

Primary outcomes:
measure: Frontal Assessment Battery
timeFrame: 3 months
Secondary outcomes:
measure: Trial Making Test
timeFrame: 3 months
Other outcomes:
Locations:
city: Messina
country: Italy
facility: IRCCS Centro Neurolesi "Bonino-Pulejo"
Study officials:
affiliation: IRCCS Centro Neurolesi
name: Rocco S Calabrò
role: STUDY_CHAIR
References:
Clinical trial NCT04292613: "The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"
Official title: The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemiplegic Shoulder Pain
Keywords: shoulder pain, hemiplegic, function, balance
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2020-03-03
Enrollment: 48
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: hemiplegic shoulder pain

Brief summary: "The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"

Detailed description: Hemiplegic shoulder pain is a common symptom. Our aim in this study is to investigate the relationship between hemiplegic shoulder pain and balance and upper extremity functions.

Eligibility criteria: Inclusion Criteria:

* Having had a cerebrovascular accident
* Ages ranging from 40 to 75
* Right or left hemiplegic
* Without mental problems
* Cooperative
* According to Brunnstrom staging, upper extremity stage 1-2-3-4-5

Exclusion Criteria:

* who do not want to be evaluated
* Under the age of 40 and over the age of 75
* Non-cooperative
* Another orthopedic shoulder problem
* Newly operated patients will not be included in the study.

Primary outcomes:
measure: Upper Extremite Fugl-Meyer Assessment (UA-FMA)
timeFrame: 1 day (Evaluation will be done once)
Secondary outcomes:
measure: McGill Melzack Pain Questionnaire
timeFrame: 1 day (Evaluation will be done once)
measure: Short Form- 36
timeFrame: 1 day (Evaluation will be done once)
measure: Berg Balance Scale
timeFrame: 1 day (Evaluation will be done once)
Other outcomes:
Locations:
city: Bahçelievler
country: Turkey
facility: Istanbul Physical Therapy and Rehabilitation Training and Research Hospital
state: Istanbul
Study officials:
affiliation: istanbul physical therapy and rehabilitation training and research hospital
name: Sibel Gayretli Atan
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02000713: Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)
Official title: Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Amyotrophic Lateral Sclerosis
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2013-12-04
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The investigators want to know if magnetic resonance imaging can accurately provide an early diagnosis of amyotrophic lateral sclerosis (ALS).

Detailed description: Currently there is no definitive diagnostic test for amyotrophic lateral sclerosis (ALS). The investigators' goal is to determine if magnetic resonance imaging can provide an accurate diagnosis of ALS by looking at chemical concentrations in the spinal cord at the neck level which show up in MRI imaging and compare these chemical concentrations to corresponding measures in healthy control subjects.

Eligibility criteria: Inclusion Criteria:

1. Adults age 18 to 80 years of age.

Exclusion Criteria:

1. Do not have active substance abuse
2. Do not have co-morbid psychiatric disease
3. Do not have opportunistic central nervous system infection
4. Do not have cerebrovascular disease
5. Do not have a contraindication for magnetic resonance imaging(MRI)(e.g. cardiac pacemaker, ferromagnetic or metallic implants).
6. Are not pregnant
7. Have not had cervical spinal surgery(neck) -

Primary outcomes:
measure: Study levels of N-acetylaspartate (NAA)in the cervical spinal cord.
timeFrame: 60 minutes or as needed (rarely more than 2 hours)
Secondary outcomes:
measure: Fractional anisotropy in the cervical spinal cord
timeFrame: 3 years
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Hospital
state: Michigan
Study officials:
affiliation: University of Michigan Hospital
name: Bradley Foerster, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00647413: Prevent Exposure to Tobacco Smoke at Home [Gesunde Atemluft zu Hause]
Official title: Cancer Prevention by Reducing Exposure to Environmental Tobacco Smoke at Home
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Smoking
Passive Smoking
Exposure to Environmental Smoke
Keywords: smoking
passive smoking
exposure to environmental smoke
home smoking ban
urinary cotinine
Lead sponsor: University Medicine Greifswald
Sponsor class: OTHER
Collaborators: name: Deutsche Krebshilfe e.V., Bonn (Germany)
First posted: 2008-03-31
Enrollment: 6000
Sex: ALL
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: Background: Infants are at risk for tobacco-attributable diseases by being exposed to environmental tobacco smoke (ETS). International literature has shown that a home smoking ban can reduce ETS. The purpose of this study is to examine whether a brief feedback about urinary cotinine in infants and a counselling session about the consequences of ETS leads to a reduction of ETS.

All families with children up to an age of three years in the study region will be contacted by mail and asked for participation in this study. They will be randomised into an intervention and one control group. The intervention group will receive a ETS counselling session and detailed analysis of urinary cotinine (a biomarker of ETS) at their home. They will further receive written feedback approx. 2 weeks later. The control group will be visited and will answer a questionnaire and will receive brochures about ETS. They will receive a standard analysis feedback of urinary cotinine. There will be oine further assessment/ visit 12 months later. The outcome of this study is an anlysis of urinary cotinine and smoking behaviour and changes in cotinine and smoking behaviour.


Eligibility criteria: Inclusion Criteria:

* born in 2005, 2006 or 2007,
* being exposed to environmental tobacco smoke at home by at least one parent, living in the study region of west pommerania

Exclusion Criteria:

Primary outcomes:
measure: exposure to environmental tobacco smoke
timeFrame: 6 months
Secondary outcomes:
measure: smoking behaviour
timeFrame: 6 months
Other outcomes:
Locations:
city: Greifswald
country: Germany
facility: Institut für Epidemiologie und Sozialmedizin
state: MV
Study officials:
affiliation: Institut für Epidemiologie und Sozialmedizin, University of Greifswald
name: Ulrich John, Prof. Dr.
role: STUDY_DIRECTOR
affiliation: Institut für Epidemiologie und Sozialmedizin
name: Jochen René Thyrian, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ulbricht S, Gross S, Meyer C, Hannover W, Nauck M, John U. Reducing tobacco smoke exposure in children aged below 4 years - a randomized controlled trial. Prev Med. 2014 Dec;69:208-13. doi: 10.1016/j.ypmed.2014.10.016. Epub 2014 Oct 18.
Clinical trial NCT00562913: Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
Official title: Phase I Open-label, Non-randomized, Non-placebo Controlled Study to Determine the Safety, Pharmacokinetics, and Tumor Response Profile of Sorafenib as Continuous Dosing in Combination With Cyclophosphamide and Doxorubicin in Patients With Advanced, Refractory Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cancer
Keywords: Cancer
Sorafenib
Cyclophosphamide
Doxorubicin
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2007-11-26
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study to access the safety, levels of drug in the blood and tumor effects of sorafenib dosed daily combined with Cyclophosphamide and Doxorubicin in cancer patients


Eligibility criteria: Inclusion Criteria:

* At least 18 years old
* Advanced histological or cytological documentation of cancer
* life-expectancy of at least 12 weeks
* able to swallow pills
* ECOG status of 0,1 or 2
* adequate bone marrow
* liver and renal function

Exclusion Criteria:

* \> NYHA Class 2 CHF
* Serious myocardial dysfunction,
* or symptomatic coronary artery disease (MI more than 6 months prior to study entry is allowed)
* History of organ allograft
* uncontrolled hypertension
* renal dialysis
* Bleeding event/hemorrhage within 4 weeks of study treatment
* major surgery within 4 weeks of study treatment
* Previous exposure to doxorubicin or other anthracyclines exceeding a maximum lifetime cumulative dose

Primary outcomes:
measure: To determine the pharmacokinetics and safety of cyclophosphamide when co-administered with 400 mg BID sorafenib and doxorubicin administered
timeFrame: 6 weeks
Secondary outcomes:
measure: To evaluate the tumor response to the combination of cyclophosphamide, doxorubicin and sorafenib
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Edmonton
country: Canada
state: Alberta
city: Montreal
country: Canada
state: Quebec
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT02337413: Urotherapy vs. Urotherapy With Constipation Treatment for Nocturnal Enuresis
Official title: A Controlled Randomized, Physician Blinded Study to Assess Isolated Uro-therapy vs. Urotherapy With Constipation Treatment for Patients With Moderate-severe Monosymptomatic Nocturnal Enuresis (MNE) Not Meeting ROME-III Constipation Criteria
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Nocturnal Enuresis
Keywords: Constipation
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2015-01-13
Enrollment: 0
Sex: ALL
Minimum age (years): 5
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Constipation treatment has been found to ameliorate symptoms in some patients with nocturnal enuresis (bed wetting at night). This study aims to explore if treatment of patients without overt constipation (As defined by the ROME III criteria) will also respond to stool softening and GI behavioral therapy with reduction of their urinary tract symptoms when added to standard urotherapy.


Eligibility criteria: Inclusion Criteria:

1. Aged 5-17 years at time of signing of informed consent.
2. MNE as defined by ≥3 wet nights/week without daytime incontinence
3. Do not meet Rome III criteria for functional constipation

Exclusion Criteria:

1. Inability to provide signed informed consent.
2. Inability to comply with the study protocol.
3. Neurogenic bladder
4. Attention Deficit Disorder (ADD or ADHD) on medical treatment.
5. Known significant sacral, perineal, or other congenital or surgical defect.
6. Known orthopedic/neurological disease which may affect urinary continence, cause constipation, or affect reading of abdominal x-rays. (e.g. spastic cerebral palsy, severe scoliosis)
7. Patient taking medicinal drugs which can cause urinary incontinence or constipation.

Primary outcomes:
measure: Number of participants with complete (no nocturnal enuresis) or partial (A decease in nocturnal enuresis episodes of 50% or more) response at week 14
timeFrame: 14 weeks
Secondary outcomes:
measure: Number of participants with complete (no nocturnal enuresis) or Partial (A decease in nocturnal enuresis episodes of 50% or more) response of enuresis to treatment in patient subgroups with fecal loading compared to those without fecal loading.
timeFrame: 14 weeks
measure: Number of participants with sustained complete (no nocturnal enuresis) or partial (A decease in nocturnal enuresis episodes of 50% or more) response 12 weeks after the end of the intervention.
timeFrame: 26 weeks
measure: Number of participants with adverse effects
timeFrame: 14 weeks
Other outcomes:
Locations:
city: Petach Tikva
country: Israel
facility: Institute of Gastroenterology, Nutrition and Liver Diseases; Schneider Children's Medical Center of Israel
Study officials:
References:
citation: Hodges SJ, Anthony EY. Occult megarectum--a commonly unrecognized cause of enuresis. Urology. 2012 Feb;79(2):421-4. doi: 10.1016/j.urology.2011.10.015. Epub 2011 Dec 14.
Clinical trial NCT00739713: Effects of Sea Buckthorn Oil on Dry Eye
Official title: Effects of Sea Buckthorn Oil on Dry Eye
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Eye Syndromes
Keywords: dry eye
sea buckthorn
Hippophaë
Lead sponsor: University of Turku
Sponsor class: OTHER
Collaborators: name: Turku Municipal Health Department/evo-funding
name: Turku University Hospital
name: Finnsusp Ltd.
name: Aromtech Ltd.
name: Shiny Horse Ltd
name: Valioravinto Ltd
name: The Finnish Funding Agency for Technology and Innovation (TEKES)
First posted: 2008-08-22
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective is to study the effect of sea buckthorn oil on dry eye.

Detailed description: The objective is to study whether regular consumption of sea buckthorn berry oil can relieve the symptoms of dry eye syndrome. The study design is a parallel randomized double-blind placebo controlled trial. The participants daily consume sea buckthorn or placebo oil for 3 months. The dry eye symptoms will be monitored during the study using a validated questionnaire. In addition clinical dry eye tests are made by an ophthalmologist three time during the study. Samples will be taken for tear film lipid and cytokine analyses. Blood samples for the analyses of inflammatory markers are also obtained. The cytokine and other inflammation marker analyses are optional. The symptoms will be monitored and clinical tests made also 4 weeks after the participants have stopped consuming the study oils.

Eligibility criteria: Inclusion Criteria:

* Dry eye symptoms

Exclusion Criteria:

* Severe illness
* Anticholinergic drugs
* Smoking

Primary outcomes:
measure: Symptom severity: symptom questionnaires and clinical dry eye tests
timeFrame: 3 months intervention + 1 month after the intervention
Secondary outcomes:
measure: Tear film lipid profile, tear cytokines, inflammation mediators in blood
timeFrame: 3 months intervention + 1 month after the intervention
Other outcomes:
Locations:
city: Turku
country: Finland
facility: University of Turku
Study officials:
affiliation: University of Turku
name: Heikki P Kallio, Professor
role: STUDY_DIRECTOR
References:
citation: Yang B, Kalimo KO, Mattila LM, Kallio SE, Katajisto JK, Peltola OJ, Kallio HP. Effects of dietary supplementation with sea buckthorn (Hippophae rhamnoides) seed and pulp oils on atopic dermatitis. J Nutr Biochem. 1999 Nov;10(11):622-30. doi: 10.1016/s0955-2863(99)00049-2.
citation: Larmo PS, Jarvinen RL, Setala NL, Yang B, Viitanen MH, Engblom JR, Tahvonen RL, Kallio HP. Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry eye. J Nutr. 2010 Aug;140(8):1462-8. doi: 10.3945/jn.109.118901. Epub 2010 Jun 16.